These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 19104492

  • 1. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [Abstract] [Full Text] [Related]

  • 2. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 3. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 4. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 6. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
    Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y, Tanosaki R, Mineishi S.
    Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
    [Abstract] [Full Text] [Related]

  • 7. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
    Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ.
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
    [Abstract] [Full Text] [Related]

  • 8. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [Abstract] [Full Text] [Related]

  • 9. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, Ohta K, Hino M.
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [Abstract] [Full Text] [Related]

  • 10. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, Russell NH.
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [Abstract] [Full Text] [Related]

  • 11. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A, Nannya Y, Sakata-Yanagimoto M, Oshima K, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.
    Nivison-Smith I, Dodds AJ, Butler J, Bradstock KF, Ma DD, Simpson JM, Szer J.
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):302-8. PubMed ID: 21620988
    [Abstract] [Full Text] [Related]

  • 13. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
    Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J, Shigematsu A, Kondo T, Yamamoto S, Endo T, Nishio M, Ito YM, Tanaka J, Koike T, Asaka M, Imamura M.
    Am J Hematol; 2010 Apr; 85(4):243-8. PubMed ID: 20162540
    [Abstract] [Full Text] [Related]

  • 14. Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.
    Majhail NS, Parks K, Defor TE, Weisdorf DJ.
    Bone Marrow Transplant; 2006 Dec; 38(11):765-8. PubMed ID: 17028622
    [Abstract] [Full Text] [Related]

  • 15. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 16. Time-course and risk factors of hypothyroidism following allogeneic hematopoietic stem cell transplantation (HSCT) in children conditioned with fractionated total body irradiation.
    Bailey HK, Kappy MS, Giller RH, Gralla J.
    Pediatr Blood Cancer; 2008 Sep; 51(3):405-9. PubMed ID: 18523993
    [Abstract] [Full Text] [Related]

  • 17. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS, van der Heiden PL, Barge RM, Houtzager S, Lankester AC, van Tol MJ, Kroes AC.
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [Abstract] [Full Text] [Related]

  • 18. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M, McGlave PB, Burns LJ, Miller JS, Barke JN, Defor TE, Weisdorf DJ.
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [Abstract] [Full Text] [Related]

  • 19. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.
    Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G, Kato K, Mineishi S.
    Bone Marrow Transplant; 2009 Nov; 44(9):579-83. PubMed ID: 19308041
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic hematopoietic cell transplantation for metastatic breast cancer.
    Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D.
    Bone Marrow Transplant; 2008 Mar; 41(6):537-45. PubMed ID: 18084340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.